TY - JOUR
T1 - Neurotensin agonists
T2 - Potential in the treatment of schizophrenia
AU - Boules, Mona
AU - Shaw, Amanda
AU - Fredrickson, Paul
AU - Richelson, Elliott
N1 - Funding Information:
This essay aims to contribute to this on-going process of “defining digital art history and its relationship to the larger fields of digi- tal humanities and art history.”7 We coin the expression “slow digital art history” for describing our research methodology and philosophy.8 In doing so, we do not wish to imply that there is some kind of “fast digital art history” – let alone one that would be of inferior quality. We simply want to highlight that our use of digital tools is preceded, inspired, and fueled by a time-consuming process of searching, collecting, organizing, and processing a vast amount and a wide array of archival documents containing rich yet complex data. This process is, for all intents and purposes, slow. In this essay, we introduce MapTap. Mapping the Antwerp-Brussels-Oudenarde Tapestry Complex via Network Analysis (1620 – 1720), an ongoing international and interdisciplinary research project funded by KU Leuven and the Flemish Science Foundation (FWO-Vlaanderen) (2012 – 2016).9 We first show that MapTap’s research questions and methodology are traditionally materialist. In the second part, we introduce the booming yet still slightly amorphous field and methodological framework in which Map-Tap operates, that is, formal historical network research (HNR).10 After a discussion of some key precepts and challenges of HNR, we introduce, in the third part, our custom-made digital tool underpinning MapTap’s research ambitions. This tool is a database named Cornelia. Finally, a case study that removes or at least mitigates traditional layers of bias against women shows one way in which Cornelia can help us to come to an inclusive understanding of the interplay be- tween the dynamics of social structure on the one hand and artistic developments in Flemish tapestry on the other.
Funding Information:
4 Diane M. Zorich, Digital Art History: A Community Assessment, in: Visual Resources 29, 2013, 14–21. The 2011 survey was sponsored by the Samuel H. Kress Foundation in conjunction with the Roy Rosenzweig Center for History and New Media at George Mason University, Fairfax, Virginia.
PY - 2007
Y1 - 2007
N2 - Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the biology of schizophrenia. It is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including schizophrenia. This review outlines the neurochemistry and function of the NT system and the data implicating its role in schizophrenia. The data suggest that NT receptor agonists have the potential to be used as novel therapeutic agents for the treatment of schizophrenia, with the added benefits of (i) not causing weight gain, an adverse effect that is problematic with some of the currently used atypical antipsychotic drugs; and (ii) helping patients to stop smoking, a behaviour that is highly prevalent in those with schizophrenia.
AB - Neurotensin (NT) is a neuropeptide that, for decades, has been implicated in the biology of schizophrenia. It is closely associated with, and is thought to modulate, dopaminergic and other neurotransmitter systems involved in the pathophysiology of various neuropsychiatric diseases, including schizophrenia. This review outlines the neurochemistry and function of the NT system and the data implicating its role in schizophrenia. The data suggest that NT receptor agonists have the potential to be used as novel therapeutic agents for the treatment of schizophrenia, with the added benefits of (i) not causing weight gain, an adverse effect that is problematic with some of the currently used atypical antipsychotic drugs; and (ii) helping patients to stop smoking, a behaviour that is highly prevalent in those with schizophrenia.
UR - http://www.scopus.com/inward/record.url?scp=33846090164&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846090164&partnerID=8YFLogxK
U2 - 10.2165/00023210-200721010-00002
DO - 10.2165/00023210-200721010-00002
M3 - Review article
C2 - 17190526
AN - SCOPUS:33846090164
SN - 1172-7047
VL - 21
SP - 13
EP - 23
JO - CNS Drugs
JF - CNS Drugs
IS - 1
ER -